Ragul Gowthaman

Ragul Gowthaman

Auto-generated profile, based on publicly available information

Ragul Gowthaman

W.M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Nature Methods
Verified
Journal Article
Closed access
PDF file
JLJulia Koehler Leman
Julia Koehler Leman
BWBrian D. Weitzner
Brian D. Weitzner
SLSteven M. Lewis
Steven M. Lewis
JAJared Adolf-Bryfogle
Jared Adolf-Bryfogle
NANawsad Alam
Nawsad Alam
RBRichard Bonneau
Richard Bonneau

24 April 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
XWXiaoqing Wu
Xiaoqing Wu
GGGulhumay Gardashova
Gulhumay Gardashova
LLLan Lan
Lan Lan
SHShuang Han
Shuang Han
CZCuncong Zhong
Cuncong Zhong
LXLiang Xu
Liang Xu
Patients diagnosed with metastatic breast cancer have a dismal 5-year survival rate of only 24%. The RNA-binding protein Hu antigen R (HuR) is upregulated in breast cancer, and elevated cytoplasmic HuR correlates with high-grade tumors and poor clinical outcome of breast cancer. HuR promotes tumorigenesis by regulating numerous proto-oncogenes, growth factors, and cytokines that support major tumor hallmarks including invasion and metastasis. Here, we report a HuR inhibitor KH-3, which potently suppresses breast cancer cell growth and invasion. Furthermore, KH-3 inhibits breast cancer experimental lung metastasis, improves mouse survival, and reduces orthotopic tumor growth. Mechanistically, we identify FOXQ1 as a direct target of HuR. KH-3 disrupts HuR–FOXQ1 mRNA interaction, leading to inhibition of breast cancer invasion. Our study suggests that inhibiting HuR is a promising therapeutic strategy for lethal metastatic breast cancer.

14 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JDJay Daniels
Jay Daniels
PDPeter G. Doukas
Peter G. Doukas
MEMaria E. Martinez Escala
Maria E. Martinez Escala
KRKimberly G. Ringbloom
Kimberly G. Ringbloom
DSDavid J. H. Shih
David J. H. Shih
JCJaehyuk Choi
Jaehyuk Choi
Primary cutaneous γδ T cell lymphomas (PCGDTLs) represent a heterogeneous group of uncommon but aggressive cancers. Herein, we perform genome-wide DNA, RNA, and T cell receptor (TCR) sequencing on 29 cutaneous γδ lymphomas. We find that PCGDTLs are not uniformly derived from Vδ2 cells. Instead, the cell-of-origin depends on the tissue compartment from which the lymphomas are derived. Lymphomas arising from the outer layer of skin are derived from Vδ1 cells, the predominant γδ cell in the epidermis and dermis. In contrast, panniculitic lymphomas arise from Vδ2 cells, the predominant γδ T cell in the fat. We also show that TCR chain usage is non-random, suggesting common antigens for Vδ1 and Vδ2 lymphomas respectively. In addition, Vδ1 and Vδ2 PCGDTLs harbor similar genomic landscapes with potentially targetable oncogenic mutations in the JAK/STAT, MAPK, MYC, and chromatin modification pathways. Collectively, these findings suggest a paradigm for classifying, staging, and treating these diseases.

9 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DWDaichao Wu
Daichao Wu
DGD. Travis Gallagher
D. Travis Gallagher
RGRagul Gowthaman
Ragul Gowthaman
BPBrian G. Pierce
Brian G. Pierce
RMRoy A. Mariuzza
Roy A. Mariuzza
Adoptive cell therapy (ACT) with tumor-specific T cells can mediate cancer regression. The main target of tumor-specific T cells are neoantigens arising from mutations in self-proteins. Although the majority of cancer neoantigens are unique to each patient, and therefore not broadly useful for ACT, some are shared. We studied oligoclonal T-cell receptors (TCRs) that recognize a shared neoepitope arising from a driver mutation in the p53 oncogene (p53R175H) presented by HLA-A2. Here we report structures of wild-type and mutant p53–HLA-A2 ligands, as well as structures of three tumor-specific TCRs bound to p53R175H–HLA-A2. These structures reveal how a driver mutation in p53 rendered a self-peptide visible to T cells. The TCRs employ structurally distinct strategies that are highly focused on the mutation to discriminate between mutant and wild-type p53. The TCR–p53R175H–HLA-A2 complexes provide a framework for designing TCRs to improve potency for ACT without sacrificing specificity.

10 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DWDaichao Wu
Daichao Wu
AKAlexander Kolesnikov
Alexander Kolesnikov
RYRui Yin
Rui Yin
JGJohnathan Guest
Johnathan Guest
RGRagul Gowthaman
Ragul Gowthaman
RMRoy A. Mariuzza
Roy A. Mariuzza
T cells play a vital role in combatting SARS-CoV-2 and forming long-term memory responses. Whereas extensive structural information is available on neutralizing antibodies against SARS-CoV-2, such information on SARS-CoV-2-specific T-cell receptors (TCRs) bound to their peptide–MHC targets is lacking. Here we determine the structures of a public and a private TCR from COVID-19 convalescent patients in complex with HLA-A2 and two SARS-CoV-2 spike protein epitopes (YLQ and RLQ). The structures reveal the basis for selection of particular TRAV and TRBV germline genes by the public but not the private TCR, and for the ability of the TCRs to recognize natural variants of RLQ but not YLQ. Neither TCR recognizes homologous epitopes from human seasonal coronaviruses. By elucidating the mechanism for TCR recognition of an immunodominant yet variable epitope (YLQ) and a conserved but less commonly targeted epitope (RLQ), this study can inform prospective efforts to design vaccines to elicit pan-coronavirus immunity.

1 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
EREve Richardson
Eve Richardson
YAYannick Jurriaan Maria Aarts
Yannick Jurriaan Maria Aarts
JAJohn A Altin
John A Altin
CBCoos A. B. Baakman
Coos A. B. Baakman
PBPhilip Bradley
Philip Bradley
BPBjoern Peters
Bjoern Peters
T cell receptors (TCRs) can bind to peptides presented by MHC molecules (pMHC) as a first step to trigger a T cell response. Reliable approaches to predict TCR:pMHC binding would have broad applications in clinical diagnostics, therapeutics, and the fundamental understanding of molecular interactions. IMMREP is a community organized series of prediction contests that asks participants to predict TCR:pMHC binding on unpublished datasets. Previous iterations in 2022 and 2023 showed multiple approaches can predict TCR-pMHC binding with significant accuracy (median AUC_0.1≥0.7) for peptides where experimental data is available (“seen” peptides). In contrast, models did not outperform random guessing for peptides that have no such data available (“unseen” peptides). Here we report on the results of IMMREP25, which focused solely on unseen peptides in order to evaluate the cutting edge of the field. We received 126 named submissions predicting the specificity of 1,000 TCRs against twenty unseen peptides restricted by one of two MHC molecules (HLA-A*02:01 and HLA-B*40:01). The best performing methods showed a macro-AUC_0.1 of 0.60, significantly better than random, demonstrating significant advances in the field. The top performing methods incorporated structural modeling into their approach, indicating that especially for ‘unseen’ peptides, a structural understanding aids in the prediction of TCR:pMHC interactions. The results from this benchmark highlight the significant challenges remaining for TCR:pMHC predictions and will inform future method development.